Relovair PD PK in Chinese Healthy Subjects

Summary

In this study, fluticasone furoate (FF) and vilanterol (VI) in different dose combinations (50/25mcg, 100/25mcg and 200/25mcg) will be administered from a single dry powder device to evaluate the PD, PK, safety and tolerability of the combination in healthy Chinese subjects. The information gathered will be used as a support of the clinical development program of the fixed dose combination of FF/VI inhalation powder in Chinese population.

Timeline

Start

2012-12-05

Primary completion

2013-06-04

Completion

2013-06-04

Drugs

Indications